Search Results

Your search for Karen Lisa Smith, MD, MPH, and Vered Stearns, MD,Karen Lisa Smith, MD, MPH, and Vered Stearns, MD matches 2 pages

Showing 1 - 2

By Karen Lisa Smith, MD, MPH, and Vered Stearns, MD / March 15, 2014

Impact of Delayed Initiation of Adjuvant Chemotherapy for Breast Cancer Varies by Tumor Subtype

The optimal time interval between surgery and initiation of adjuvant chemotherapy for early-stage breast cancer is not well established. Although most physicians aim to initiate adjuvant chemotherapy within a few weeks of surgery, clinical factors may cause delay. The influence of delay on relapse...

breast cancer

By Karen Lisa Smith, MD, MPH, and Vered Stearns, MD / June 25, 2014

A New Era in the Management of Advanced HER2-Positive Breast Cancer

Approximately 20% of all breast cancers are human epidermal growth factor receptor 2 (HER2)-positive. Prior to the era of HER2-targeted therapy, HER2-positive breast cancer was characterized by a poor prognosis.1,2 The development of the first HER2-targeted therapy, trastuzumab (Herceptin), led to...

Nov

Today In Oncology

Search Results

Your search for Karen Lisa Smith, MD, MPH, and Vered Stearns, MD,Karen Lisa Smith, MD, MPH, and Vered Stearns, MD matches 2 pages

Impact of Delayed Initiation of Adjuvant Chemotherapy for Breast Cancer Varies by Tumor Subtype

A New Era in the Management of Advanced HER2-Positive Breast Cancer

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?

International Cancer Organizations Present Collaborative Work During Oncology Event in China

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

Suicide-Related Mortality in Male AYA Cancer Survivors

Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC